After TauRx Pharmaceutics’ investigational Alzheimer’s treatment hydromethylthionine mesylate (HMTM) was found to slow the disease’s progression it could, if approved, become the first oral treatment targeting the tau protein.

Novo Nordisk’s diabetes treatment Rybelsus (semaglutide) has been found to significantly reduce the risk of major adverse cardiovascular events (MACE).

Johnson & Johnson’s Darzalex (daratumumab) could help patients with newly diagnosed multiple myeloma (NDMM) approach normal life expectancy without their disease progressing.

Indian biotechnology company Eyestem Research has achieved successful results from a phase 1 trial of Eyecyte-RPE, its potential therapy for a rare, advanced form of dry age-related macular degeneration (AMD).

Corcept Therapeutics’ oral ovarian cancer drug relacorilant has improved progression-free survival in the ROSELLA trial.

Recce Pharmaceuticals has announced positive patient data from its phase 2 clinical trial into RECCE 327 (R327), for the treatment of acute bacterial skin and skin structure infections (ABSSSIs), including diabetic foot infections (DFI).

Paragon Bioscience’s clinical biopharma spin-out, Emalex Bioscience, has announced that its lead candidate for the treatment of Tourette syndrome has met its primary and secondary endpoints in a recent phase 3 study.

Ophthalmology biotech PulseSight Therapeutics has confirmed the closure of its Series A funding round, the proceeds of which will be used to fund a phase 1 study into its dry age-related macular degeneration (AMD) therapy, PST-611. The funding round was supported by existing investor Pureos BioVentures.

Real-world data into a mandatory non-medical switching policy for patients with inflammatory bowel disease (IBD) has shown long-term safety and efficacy. The patients transitioned from using adalimumab (Humira) to a biosimilar due to the enaction of the policy in British Columbia, Canada – the first Canadian province to do so.

Aplagon, a clinical stage biopharmaceutical company dedicated to the development of first-in-class therapeutics for thrombo-inflammatory diseases, has announced the closing of a €7m financing round for the initiation of phase 2a of its clinical trials.

Swedish biopharmaceutical company AnaCardio has announced the completion of a Series A extension financing round that has raised $19m for its novel contractile agents. The round was co-led by Novo Holdings, Pureos Bioventures and Sound Bioventures.

Beckley Psytech Ltd, a clinical-stage biopharmaceutical company that specialises in the production of accessible medicines for mental health conditions, has announced positive results for the phase 2a study into BPL-003 in patients with moderate-to-severe alcohol use disorder (AUD).